Mantle Cell


The drug has been approved for treatment-naive patients who are ineligible for transplant.
Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.
The approval extends the use of bortezomib beyond relapsed and refractory patients.
Velcade (bortezomib), developed by Millenium Pharmaceuticals, is a proteasome inhibitor that is currently approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma. Several abstracts were presented at the annual meeting of the American Society of Clinical Oncology this year for its use in other indications.


January 23rd - 25th, 2014
San Francisco , CA
February 15th -18th, 2014
San Diego, CA
Diabetes Compendium
Oncology Compendium